

Tumor Immunity Therapy Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/T08F9E2FCA81EN.html>

Date: August 2022

Pages: 105

Price: US\$ 3,250.00 (Single User License)

ID: T08F9E2FCA81EN

Abstracts

This report contains market size and forecasts of Tumor Immunity Therapy in Global, including the following market information:

Global Tumor Immunity Therapy Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Tumor Immunity Therapy market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Immune Checkpoint Inhibitor Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Tumor Immunity Therapy include Bristol-Myers Squibb, Merck & Co., Inc., Roche AG, AstraZeneca, Plc, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc. and IMVAQ Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Tumor Immunity Therapy companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Tumor Immunity Therapy Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Tumor Immunity Therapy Market Segment Percentages, by Type, 2021 (%)

Immune Checkpoint Inhibitor

Cytokine Immunotherapy

Cancer Vaccine

Car-t Cell Therapy

Others

Global Tumor Immunity Therapy Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Tumor Immunity Therapy Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Global Tumor Immunity Therapy Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Tumor Immunity Therapy Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Tumor Immunity Therapy revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Tumor Immunity Therapy revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Bristol-Myers Squibb

Merck & Co., Inc.

Roche AG

AstraZeneca, Plc

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

IMVAQ Therapeutics

Arch Oncology

Juno Therapeutics

Refuge

Lepu Biopharma

Genoimmune

TCR Cure

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Tumor Immunity Therapy Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Tumor Immunity Therapy Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL TUMOR IMMUNITY THERAPY OVERALL MARKET SIZE

- 2.1 Global Tumor Immunity Therapy Market Size: 2021 VS 2028
- 2.2 Global Tumor Immunity Therapy Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Tumor Immunity Therapy Players in Global Market
- 3.2 Top Global Tumor Immunity Therapy Companies Ranked by Revenue
- 3.3 Global Tumor Immunity Therapy Revenue by Companies
- 3.4 Top 3 and Top 5 Tumor Immunity Therapy Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Tumor Immunity Therapy Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Tumor Immunity Therapy Players in Global Market
 - 3.6.1 List of Global Tier 1 Tumor Immunity Therapy Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Tumor Immunity Therapy Market Size Markets, 2021 & 2028

4.1.2 Immune Checkpoint Inhibitor

4.1.3 Cytokine Immunotherapy

4.1.4 Cancer Vaccine

4.1.5 Car-t Cell Therapy

4.1.6 Others

4.2 By Type - Global Tumor Immunity Therapy Revenue & Forecasts

4.2.1 By Type - Global Tumor Immunity Therapy Revenue, 2017-2022

4.2.2 By Type - Global Tumor Immunity Therapy Revenue, 2023-2028

4.2.3 By Type - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Tumor Immunity Therapy Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.2 By Application - Global Tumor Immunity Therapy Revenue & Forecasts

5.2.1 By Application - Global Tumor Immunity Therapy Revenue, 2017-2022

5.2.2 By Application - Global Tumor Immunity Therapy Revenue, 2023-2028

5.2.3 By Application - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Tumor Immunity Therapy Market Size, 2021 & 2028

6.2 By Region - Global Tumor Immunity Therapy Revenue & Forecasts

6.2.1 By Region - Global Tumor Immunity Therapy Revenue, 2017-2022

6.2.2 By Region - Global Tumor Immunity Therapy Revenue, 2023-2028

6.2.3 By Region - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Tumor Immunity Therapy Revenue, 2017-2028

6.3.2 US Tumor Immunity Therapy Market Size, 2017-2028

6.3.3 Canada Tumor Immunity Therapy Market Size, 2017-2028

6.3.4 Mexico Tumor Immunity Therapy Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Tumor Immunity Therapy Revenue, 2017-2028

6.4.2 Germany Tumor Immunity Therapy Market Size, 2017-2028

- 6.4.3 France Tumor Immunity Therapy Market Size, 2017-2028
- 6.4.4 U.K. Tumor Immunity Therapy Market Size, 2017-2028
- 6.4.5 Italy Tumor Immunity Therapy Market Size, 2017-2028
- 6.4.6 Russia Tumor Immunity Therapy Market Size, 2017-2028
- 6.4.7 Nordic Countries Tumor Immunity Therapy Market Size, 2017-2028
- 6.4.8 Benelux Tumor Immunity Therapy Market Size, 2017-2028
- 6.5 Asia
 - 6.5.1 By Region - Asia Tumor Immunity Therapy Revenue, 2017-2028
 - 6.5.2 China Tumor Immunity Therapy Market Size, 2017-2028
 - 6.5.3 Japan Tumor Immunity Therapy Market Size, 2017-2028
 - 6.5.4 South Korea Tumor Immunity Therapy Market Size, 2017-2028
 - 6.5.5 Southeast Asia Tumor Immunity Therapy Market Size, 2017-2028
 - 6.5.6 India Tumor Immunity Therapy Market Size, 2017-2028
- 6.6 South America
 - 6.6.1 By Country - South America Tumor Immunity Therapy Revenue, 2017-2028
 - 6.6.2 Brazil Tumor Immunity Therapy Market Size, 2017-2028
 - 6.6.3 Argentina Tumor Immunity Therapy Market Size, 2017-2028
- 6.7 Middle East & Africa
 - 6.7.1 By Country - Middle East & Africa Tumor Immunity Therapy Revenue, 2017-2028
 - 6.7.2 Turkey Tumor Immunity Therapy Market Size, 2017-2028
 - 6.7.3 Israel Tumor Immunity Therapy Market Size, 2017-2028
 - 6.7.4 Saudi Arabia Tumor Immunity Therapy Market Size, 2017-2028
 - 6.7.5 UAE Tumor Immunity Therapy Market Size, 2017-2028

7 PLAYERS PROFILES

- 7.1 Bristol-Myers Squibb
 - 7.1.1 Bristol-Myers Squibb Corporate Summary
 - 7.1.2 Bristol-Myers Squibb Business Overview
 - 7.1.3 Bristol-Myers Squibb Tumor Immunity Therapy Major Product Offerings
 - 7.1.4 Bristol-Myers Squibb Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.1.5 Bristol-Myers Squibb Key News
- 7.2 Merck & Co., Inc.
 - 7.2.1 Merck & Co., Inc. Corporate Summary
 - 7.2.2 Merck & Co., Inc. Business Overview
 - 7.2.3 Merck & Co., Inc. Tumor Immunity Therapy Major Product Offerings
 - 7.2.4 Merck & Co., Inc. Tumor Immunity Therapy Revenue in Global Market (2017-2022)

- 7.2.5 Merck & Co., Inc. Key News
- 7.3 Roche AG
 - 7.3.1 Roche AG Corporate Summary
 - 7.3.2 Roche AG Business Overview
 - 7.3.3 Roche AG Tumor Immunity Therapy Major Product Offerings
 - 7.3.4 Roche AG Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.3.5 Roche AG Key News
- 7.4 AstraZeneca, Plc
 - 7.4.1 AstraZeneca, Plc Corporate Summary
 - 7.4.2 AstraZeneca, Plc Business Overview
 - 7.4.3 AstraZeneca, Plc Tumor Immunity Therapy Major Product Offerings
 - 7.4.4 AstraZeneca, Plc Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.4.5 AstraZeneca, Plc Key News
- 7.5 Sanofi S.A.
 - 7.5.1 Sanofi S.A. Corporate Summary
 - 7.5.2 Sanofi S.A. Business Overview
 - 7.5.3 Sanofi S.A. Tumor Immunity Therapy Major Product Offerings
 - 7.5.4 Sanofi S.A. Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.5.5 Sanofi S.A. Key News
- 7.6 Dendreon Pharmaceuticals
 - 7.6.1 Dendreon Pharmaceuticals Corporate Summary
 - 7.6.2 Dendreon Pharmaceuticals Business Overview
 - 7.6.3 Dendreon Pharmaceuticals Tumor Immunity Therapy Major Product Offerings
 - 7.6.4 Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.6.5 Dendreon Pharmaceuticals Key News
- 7.7 Novartis
 - 7.7.1 Novartis Corporate Summary
 - 7.7.2 Novartis Business Overview
 - 7.7.3 Novartis Tumor Immunity Therapy Major Product Offerings
 - 7.7.4 Novartis Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.7.5 Novartis Key News
- 7.8 Gilead Sciences Inc.
 - 7.8.1 Gilead Sciences Inc. Corporate Summary
 - 7.8.2 Gilead Sciences Inc. Business Overview
 - 7.8.3 Gilead Sciences Inc. Tumor Immunity Therapy Major Product Offerings
 - 7.8.4 Gilead Sciences Inc. Tumor Immunity Therapy Revenue in Global Market (2017-2022)

- 7.8.5 Gilead Sciences Inc. Key News
- 7.9 IMVAQ Therapeutics
 - 7.9.1 IMVAQ Therapeutics Corporate Summary
 - 7.9.2 IMVAQ Therapeutics Business Overview
 - 7.9.3 IMVAQ Therapeutics Tumor Immunity Therapy Major Product Offerings
 - 7.9.4 IMVAQ Therapeutics Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.9.5 IMVAQ Therapeutics Key News
- 7.10 Arch Oncology
 - 7.10.1 Arch Oncology Corporate Summary
 - 7.10.2 Arch Oncology Business Overview
 - 7.10.3 Arch Oncology Tumor Immunity Therapy Major Product Offerings
 - 7.10.4 Arch Oncology Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.10.5 Arch Oncology Key News
- 7.11 Juno Therapeutics
 - 7.11.1 Juno Therapeutics Corporate Summary
 - 7.11.2 Juno Therapeutics Business Overview
 - 7.11.3 Juno Therapeutics Tumor Immunity Therapy Major Product Offerings
 - 7.11.4 Juno Therapeutics Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.11.5 Juno Therapeutics Key News
- 7.12 Refuge
 - 7.12.1 Refuge Corporate Summary
 - 7.12.2 Refuge Business Overview
 - 7.12.3 Refuge Tumor Immunity Therapy Major Product Offerings
 - 7.12.4 Refuge Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.12.5 Refuge Key News
- 7.13 Lepu Biopharma
 - 7.13.1 Lepu Biopharma Corporate Summary
 - 7.13.2 Lepu Biopharma Business Overview
 - 7.13.3 Lepu Biopharma Tumor Immunity Therapy Major Product Offerings
 - 7.13.4 Lepu Biopharma Tumor Immunity Therapy Revenue in Global Market (2017-2022)
 - 7.13.5 Lepu Biopharma Key News
- 7.14 Genoimmune
 - 7.14.1 Genoimmune Corporate Summary
 - 7.14.2 Genoimmune Business Overview
 - 7.14.3 Genoimmune Tumor Immunity Therapy Major Product Offerings

7.14.4 Genoimmune Tumor Immunity Therapy Revenue in Global Market (2017-2022)

7.14.5 Genoimmune Key News

7.15 TCR Cure

7.15.1 TCR Cure Corporate Summary

7.15.2 TCR Cure Business Overview

7.15.3 TCR Cure Tumor Immunity Therapy Major Product Offerings

7.15.4 TCR Cure Tumor Immunity Therapy Revenue in Global Market (2017-2022)

7.15.5 TCR Cure Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Tumor Immunity Therapy Market Opportunities & Trends in Global Market

Table 2. Tumor Immunity Therapy Market Drivers in Global Market

Table 3. Tumor Immunity Therapy Market Restraints in Global Market

Table 4. Key Players of Tumor Immunity Therapy in Global Market

Table 5. Top Tumor Immunity Therapy Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Tumor Immunity Therapy Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Tumor Immunity Therapy Revenue Share by Companies, 2017-2022

Table 8. Global Companies Tumor Immunity Therapy Product Type

Table 9. List of Global Tier 1 Tumor Immunity Therapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Tumor Immunity Therapy Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Tumor Immunity Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Tumor Immunity Therapy Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Tumor Immunity Therapy Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Tumor Immunity Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Tumor Immunity Therapy Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Tumor Immunity Therapy Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Tumor Immunity Therapy Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Tumor Immunity Therapy Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Tumor Immunity Therapy Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Tumor Immunity Therapy Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Tumor Immunity Therapy Revenue, (US\$, Mn),

2023-2028

Table 24. By Region - Asia Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Tumor Immunity Therapy Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Tumor Immunity Therapy Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Tumor Immunity Therapy Revenue, (US\$, Mn), 2023-2028

Table 30. Bristol-Myers Squibb Corporate Summary

Table 31. Bristol-Myers Squibb Tumor Immunity Therapy Product Offerings

Table 32. Bristol-Myers Squibb Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 33. Merck & Co., Inc. Corporate Summary

Table 34. Merck & Co., Inc. Tumor Immunity Therapy Product Offerings

Table 35. Merck & Co., Inc. Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 36. Roche AG Corporate Summary

Table 37. Roche AG Tumor Immunity Therapy Product Offerings

Table 38. Roche AG Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 39. AstraZeneca, Plc Corporate Summary

Table 40. AstraZeneca, Plc Tumor Immunity Therapy Product Offerings

Table 41. AstraZeneca, Plc Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 42. Sanofi S.A. Corporate Summary

Table 43. Sanofi S.A. Tumor Immunity Therapy Product Offerings

Table 44. Sanofi S.A. Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 45. Dendreon Pharmaceuticals Corporate Summary

Table 46. Dendreon Pharmaceuticals Tumor Immunity Therapy Product Offerings

Table 47. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 48. Novartis Corporate Summary

Table 49. Novartis Tumor Immunity Therapy Product Offerings

Table 50. Novartis Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 51. Gilead Sciences Inc. Corporate Summary

Table 52. Gilead Sciences Inc. Tumor Immunity Therapy Product Offerings

Table 53. Gilead Sciences Inc. Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

Table 54. IMVAQ Therapeutics Corporate Summary

- Table 55. IMVAQ Therapeutics Tumor Immunity Therapy Product Offerings
- Table 56. IMVAQ Therapeutics Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)
- Table 57. Arch Oncology Corporate Summary
- Table 58. Arch Oncology Tumor Immunity Therapy Product Offerings
- Table 59. Arch Oncology Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)
- Table 60. Juno Therapeutics Corporate Summary
- Table 61. Juno Therapeutics Tumor Immunity Therapy Product Offerings
- Table 62. Juno Therapeutics Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)
- Table 63. Refuge Corporate Summary
- Table 64. Refuge Tumor Immunity Therapy Product Offerings
- Table 65. Refuge Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)
- Table 66. Lepu Biopharma Corporate Summary
- Table 67. Lepu Biopharma Tumor Immunity Therapy Product Offerings
- Table 68. Lepu Biopharma Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)
- Table 69. Genoimmune Corporate Summary
- Table 70. Genoimmune Tumor Immunity Therapy Product Offerings
- Table 71. Genoimmune Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)
- Table 72. TCR Cure Corporate Summary
- Table 73. TCR Cure Tumor Immunity Therapy Product Offerings
- Table 74. TCR Cure Tumor Immunity Therapy Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Tumor Immunity Therapy Segment by Type in 2021
- Figure 2. Tumor Immunity Therapy Segment by Application in 2021
- Figure 3. Global Tumor Immunity Therapy Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Tumor Immunity Therapy Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Tumor Immunity Therapy Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Tumor Immunity Therapy Revenue in 2021
- Figure 8. By Type - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Tumor Immunity Therapy Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Tumor Immunity Therapy Revenue Market Share, 2017-2028
- Figure 12. US Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Tumor Immunity Therapy Revenue Market Share, 2017-2028
- Figure 16. Germany Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Tumor Immunity Therapy Revenue Market Share, 2017-2028
- Figure 24. China Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028
- Figure 28. India Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Tumor Immunity Therapy Revenue Market Share, 2017-2028

Figure 30. Brazil Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Tumor Immunity Therapy Revenue Market Share, 2017-2028

Figure 33. Turkey Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Tumor Immunity Therapy Revenue, (US\$, Mn), 2017-2028

Figure 37. Bristol-Myers Squibb Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Merck & Co., Inc. Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Roche AG Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. AstraZeneca, Plc Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Sanofi S.A. Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Dendreon Pharmaceuticals Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Novartis Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Gilead Sciences Inc. Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. IMVAQ Therapeutics Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Arch Oncology Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 47. Juno Therapeutics Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 48. Refuge Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 49. Lepu Biopharma Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 50. Genoimmune Tumor Immunity Therapy Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 51. TCR Cure Tumor Immunity Therapy Revenue Year Over Year Growth (US\$,

Mn) & (2017-2022)

I would like to order

Product name: Tumor Immunity Therapy Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/T08F9E2FCA81EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T08F9E2FCA81EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970